Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man
Currently, no vaccine exists for hepatitis C virus (HCV), a major pathogen thought to infect 170 million people globally. Many studies suggest that host T cell responses are critical for spontaneous resolution of disease, and preclinical studies have indicated a requirement for T cells in protection...
Главные авторы: | Barnes, E, Folgori, A, Capone, S, Swadling, L, Aston, S, Kurioka, A, Meyer, J, Huddart, R, Smith, K, Townsend, R, Brown, A, Antrobus, R, Ammendola, V, Naddeo, M, O'Hara, G, Willberg, C, Harrison, A, Grazioli, F, Esposito, M, Siani, L, Traboni, C, Oo, Y, Adams, D, Hill, A, Colloca, S, Nicosia, A, Cortese, R, Klenerman, P |
---|---|
Формат: | Journal article |
Язык: | English |
Опубликовано: |
American Association for the Advancement of Science
2012
|
Схожие документы
-
A highly immunogenic novel genetic vaccine against HCV
по: Del Sorbo, M, и др.
Опубликовано: (2012) -
A THERAPEUTIC VACCINE FOR HCV BASED ON NOVEL, RARE, ADENOVIRAL VECTORS
по: Kelly, C, и др.
Опубликовано: (2011) -
Hepatitis Hide and Seek
по: Barnes, E, и др.
Опубликовано: (2012) -
Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.
по: Colloca, S, и др.
Опубликовано: (2012) -
PHASE I TRIAL OF A HIGHLY IMMUNOGENIC AND DURABLE T-CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL, RARE, ADENOVIRAL VECTORS
по: Barnes, E, и др.
Опубликовано: (2011)